Fluorine-18-labeled fluciclovine PET/CT in primary and biochemical recurrent prostate cancer management

Charles Marcus, Peter Butler, Aditya Bagrodia, Suzanne Cole, Rathan M. Subramaniam

Research output: Contribution to journalReview article

Abstract

Objective: The purpose of this article is to review the utility of 18F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. COnclusion: Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.

Original languageEnglish (US)
Pages (from-to)267-276
Number of pages10
JournalAmerican Journal of Roentgenology
Volume215
Issue number2
DOIs
StatePublished - Aug 2020

Keywords

  • Fluciclovine
  • PET/CT
  • Primary
  • Prostate cancer
  • Recurrent

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Fluorine-18-labeled fluciclovine PET/CT in primary and biochemical recurrent prostate cancer management'. Together they form a unique fingerprint.

  • Cite this